COMMUNIQUÉS West-GlobeNewswire

ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights
09/08/2018
-- Completed patient enrollment in Phase III ADVOCATE trial of avacopan in ANCA-associated vasculitis -- -- Ongoing clinical trials with avacopan in C3 Glomerulopathy (C3G) and CCX140 in Focal Segmental [...]
Yield10 Bioscience Announces Second Quarter 2018 Financial Results
09/08/2018
WOBURN, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to achieve step-change improvements in crop yield to enhance global food security, today [...]
BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results
09/08/2018
BELBUCA ® Continues Its Accelerated Record Prescription Growth of 80% YOY and 31% Versus the Prior Quarter Company Provides Overview of New Plan to Capitalize on Long Term Net Revenue Potential of $200 Million For [...]
Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results
09/08/2018
Conference Call Scheduled August 9, 2018 at 4:30 p.m. EDT BERKELEY HEIGHTS, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a [...]
Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides Clinical Update
09/08/2018
MENLO PARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic [...]
Organovo Reports Fiscal First-Quarter 2019 Results; Company Outlines and Expands Key Clinical Development Goals
09/08/2018
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019 Lead IND program for Alpha-1-antitrypsin deficiency (“A1AT”) expected to commence IND-enabling studies in second half of [...]
Resonant Inc. Reports Second Quarter 2018 Financial Resultsand Provides Business Update and Financial Outlook
09/08/2018
- Secured two new customer engagements - - Increased number of devices under contract to more than 60 - - Grew number of devices under qualification to 14 - GOLETA, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Resonant Inc [...]
Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights
09/08/2018
Gimoti ™ NDA submitted to FDA on June 1 st ; awaiting 74-Day FDA filing communication letter Gender-specific patents granted for Gimoti in the European Union and Mexico SOLANA BEACH, Calif., Aug. 09, 2018 (GLOBE [...]
KemPharm, Inc. Reports Second Quarter 2018 Results
09/08/2018
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced top line results from KP415.E01 efficacy and safety trial in children with ADHD [...]
Apricus Biosciences Provides Corporate Update and Second Quarter 2018 Financial Results
09/08/2018
Company Enters Into Merger Agreement with Seelos Therapeutics, Inc. Apricus Shareholders Expected to Own ~14% of Combined Company Based on Estimated $90 Million Valuation at Closing Merger Expected to Close in Fourth [...]
Fortress Biotech Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
09/08/2018
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]
Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
09/08/2018
First of three planned Phase 3 pivotal trials now underway for Iterum’s oral antibiotic Oral sulopenem, if approved, could be the first antibiotic for uncomplicated urinary tract infections in over 20 years Top-line [...]
Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results
09/08/2018
Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage [...]
Viveve Reports Second Quarter 2018 Financial Results and Provides Corporate Update
09/08/2018
Company reports 80% growth in total quarterly revenue year-over-year Multiple clinical and regulatory milestones achieved for Viveve ® System ENGLEWOOD, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Viveve Medical Inc. ( [...]
TearLab Corporation Reports Second Quarter and First Half 2018 Financial Results
09/08/2018
SAN DIEGO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the second quarter ended June 30, 2018. All dollar [...]
Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update
09/08/2018
SANTA MONICA, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, [...]
CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update
09/08/2018
Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for [...]
Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress
09/08/2018
-- OV101 in Angelman syndrome: plan to initiate an open-label extension study (ELARA) in the fourth quarter of 2018 and discuss with regulatory authorities next steps for a registrational pathway based on positive Phase [...]
Corium Reports Third Quarter Fiscal 2018 Financial Results and Corporate Highlights
09/08/2018
MENLO PARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty [...]

Pages